The treatment of diabetes in the modern era, with its growing patient population, represents a significant challenge due to the wide range of adverse effects associated with medications that target complex biochemical processes. Consequently, researchers are investigating the hypoglycemic potential of existing drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain, fever, and various inflammatory conditions. Recent studies have shown that NSAIDs, particularly salicylates, can influence glycemia through multiple mechanisms, including inhibition of gastrointestinal enzymes, blockade of K_ATP channels, activation of AMP-activated protein kinase (AMPK), and inhibition of NF-κB signaling, among others. Accordingly, this review explores the hypoglycemic potential of NSAIDs as well as their derivatives, and the diverse mechanisms through which these molecules may influence glucose homeostasis.

Background: This study aimed to evaluate associations between baseline clinical status, radiological findings, prior medical history, procedural characteristics, and recanalization success with neurological outcome at discharge (NIHSS) and functional status at 90 days (mRS). Methods: This single-center retrospective study included 100 consecutive patients with acute ischemic stroke treated with MT within 24 h of symptom onset. Clinical data, CT perfusion parameters, comorbidities, prior therapies, and detailed procedural characteristics (including anesthesia type, recanalization grade, blood pressure variability, hemorrhagic transformation, and procedure duration) were analyzed. Nonparametric tests (Mann–Whitney U, Kruskal–Wallis) and Spearman’s rank correlation were applied. Statistical significance was set at p < 0.05. Results: Early ischemic signs on baseline imaging were associated with higher NIHSS scores at discharge and worse 90-day mRS (p < 0.05). Patients undergoing CT perfusion imaging had higher discharge NIHSS. Admission NIHSS showed a moderate positive correlation with discharge NIHSS (rho = 0.367, p = 0.003). Strong correlations were observed between NIHSS at 24 h and discharge NIHSS (rho = 0.802, p < 0.001), as well as between 24 h NIHSS and 90-day mRS (rho = 0.842, p < 0.001). Successful recanalization was significantly associated with long-term outcomes, with mTICI 3 associated with the lowest 90-day mRS scores (p = 0.003). Intraprocedural blood pressure variability, hemorrhagic transformation, infections, and in-hospital complications were all linked to higher 90-day mRS values. Prolonged procedure duration showed a weak but significant correlation with worse 90-day outcome (rho = 0.232, p = 0.020). In contrast, prior comorbidities and pre-stroke therapy were not significantly associated with outcomes. A multivariable binary logistic regression analysis identified only the NIHSS score at 24 h remained as an independent predictor of favorable functional outcome at 90 days. Conclusions: Baseline stroke severity, early neurological evolution, successful reperfusion, procedural hemodynamic stability, and prevention of in-hospital complications are strongly associated with both early neurological recovery and long-term functional outcome after mechanical thrombectomy.

Background/Objectives: Inflammation plays a role at multiple levels, contributing to tumorigenesis, cellular proliferation, cell survival, and metastasis. The established link between chronic inflammation and tumor development has shifted the therapeutic focus toward nonsteroidal anti-inflammatory drugs, which exert their effects primarily through cyclooxygenase inhibition. Methods: In the present study, the antitumor potential of novel synthesized oxaprozin derivatives was evaluated using the MTT assay. The immunomodulatory effects of the selected derivative were determined in vitro by measuring cytokine concentrations and performing flow cytometry. To investigate the inhibitory capacity of these derivatives against cyclooxygenase enzymes, an in vitro inhibition assay was conducted using fluorometric screening kits, followed by in silico validation. Results: All tested tumor cell lines exhibited sensitivity to compound 1, which demonstrated the lowest cytotoxic effect against non-cancerous mMSCs and MRC-5 cells. This compound can effectively target tumor cells, inducing potent apoptosis in 4T1 breast cancer cells through a strategic shift in the Bax/Bcl-2 balance and the downregulation of the oncogenic driver Bcl-6. Although the synthesized oxaprozin derivatives showed moderate affinity for COX-1, none of the newly synthesized compounds achieved more than 50% inhibition against COX-2 at a concentration of 100 μM. Consistently, in silico procedures validated the results of the in vitro COX inhibition assay. Conclusions: The findings of this study indicate that compound 1 has the ability to modulate immune responses under stimulated conditions, and its potent antitumor activity may not be directly related to cyclooxygenase inhibition, suggesting the involvement of COX-independent pathways.